Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin

Journal of Neurology

Volumn 254, Issue 12, 2007, Pages 1660-1665

  Pruissen, D M O ^a   Rosendaal, F R ^b   Gorter, J W ^a   Garcia, A A ^c   Kappelle, L J ^a   Algra, A ^a,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anticoagulant; Bleeding risk; Haemostasis; Ischaemic stroke; Polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN VARIANT; MENADIONE EPOXIDE; PROTHROMBIN; VENOMBIN A;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD GROUP ABO SYSTEM; BRAIN ARTERY; BRAIN ISCHEMIA; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION;

ABO BLOOD-GROUP SYSTEM; ADMINISTRATION, ORAL; AGED; ALANINE; ANTICOAGULANTS; ARTERIES; BLOOD PROTEINS; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; FIBRINOGEN; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; THREONINE; VARIATION (GENETICS);

EID: 37749001160     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-007-0609-5     Document Type: Article

References (43)

1. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W (2001) Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med 345:165-169
2. The ESPRIT Study Group (2007) Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 6:115-124
3. Anand SS, Yusuf S (1999) Oral anticoagulant therapy in patients with coronary artery disease: a metaanalysis. JAMA 282:2058-2067
4. Anwar R, Gallivan L, Edmonds SD, Markham AF (1999) Genotype/phenotype correlations for coagulation factor XIII: specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 93:897-905
5. Aronis S, Bouza H, Pergantou H, Kapsimalis Z, Platokouki H, Xanthou M (2002) Prothrombotic factors in neonates with cerebral thrombosis and intraventricular hemorrhage. Acta Paediatr Suppl 91:87-91
6. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH (1994) Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64-67
7. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA (2005) Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 106:135-140
8. Casas JP, Hingorani AD, Bautista LE, Sharma P (2004) Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18, 000 cases and 58, 000 controls. Arch Neurol 61:1652-1661
9. Castori L, Taliani MR, Agnelli G, Boschetti E, Gresele P (2005) Interactions between thrombophilic genetic mutations and clinical bleeding in patients on chronic oral anticoagulant treatment. Haematologica 90:1720-1722
10. Chimowitz MI, Lynn MJ, Howlett- Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG (2005) Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352:1305-1316
11. Corral J, Iniesta JA, Gonzalez-Conejero R, Villalon M, Vicente V (2001) Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage. Blood 97:2979-2982
12. EAFT (European Atrial Fibrillation Trial) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255-1262
13. Gallivan L, Markham AF, Anwar R (1999) The Leu564 factor XIIIA variant results in significantly lower plasma factor XIII levels than the Pro564 variant. Thromb Haemost 82:1368-1370
14. Garcia AA, van der Heijden JF, Meijers JC, Rosendaal FR, Reitsma PH (2006) The relationship between AB0 blood group and the risk of bleeding during vitamin K antagonist treatment. J Thromb Haemost 4:1418-1420
15. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, Kulozik AE (2001) Increased efficiency of mRNA 3' end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 28:389-392
16. Gorter JW, on behalf of the SPIRIT and EAFT study groups (1999) Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology 53:1319-1327
17. Hart RG, Benavente O, McBride R, Pearce LA (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131:492-501
18. Juul K, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG (2004) Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med 140:330-337
19. Komanasin N, Catto AJ, Futers TS, van Hylckama Vlieg AV, Rosendaal FR, Ariens RA (2005) A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. J Thromb Haemost 3:2487-2496
20. Komlosi K, Havasi V, Bene J, Storcz J, Stankovics J, Mohay G, Weisenbach J, Kosztolanyi G, Melegh B (2005) Increased prevalence of factor V Leiden mutation in premature but not in fullterm infants with grade I intracranial haemorrhage. Biol Neonate 87:56-59
21. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM (1993) Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503-1506
22. Lim BC, Ariens RA, Carter AM, Weisel JW, Grant PJ (2003) Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 361:1424-1431
23. Linkins LA, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139:893-900
24. Little SH, Massel DR (2003) Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev CD003464
25. Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 14:143-149
26. McCarron MO, Nicoll JA (2000) Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. Ann N Y Acad Sci 903:176-179
27. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP, Jr., Jackson CM, Pullicino P (2001) A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345:1444-1451
28. Nicolaes GA, Dahlback B (2002) Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 22:530-538
29. Olsson ML, Chester MA (1995) A rapid and simple AB0 genotype screening method using a novel B/02 versus A/02 discriminating nucleotide substitution at the AB0 locus. Vox Sang 69:242-247
30. Petaja J, Hiltunen L, Fellman V (2001) Increased risk of intraventricular hemorrhage in preterm infants with thrombophilia. Pediatr Res 49:643-646
31. Reiner AP, Schwartz SM, Frank MB, Longstreth WT Jr, Hindorff LA, Teramura G, Rosendaal FR, Gaur LK, Psaty BM, Siscovick DS (2001) Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. Stroke 32:2580-2586
32. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR (2005) A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2:e312
33. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-541
34. Saxena R, Koudstaal P (2004) Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev CD000187
35. Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA (2003) Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation 107:2326-2330
36. Sudlow C, Martinez Gonzalez NA, Kim J, Clark C (2006) Does apolipoprotein E genotype influence the risk of ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage? Systematic review and meta-analyses of 31 studies among 5961 cases and 17, 965 controls. Stroke 37:364-370
37. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group (1997) A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 42:857-865
38. Undas A, Brzezinska-Kolarz B, Brummel-Ziedins K, Musial J, Szczeklik A, Mann KG (2005) Factor XIII Val34Leu polymorphism and gammachain cross-linking at the site of microvascular injury in healthy and coumarin-treated subjects. J Thromb Haemost 3:2015-2021
39. van 't Hooft FM, von Bahr SJ, Silveira A, Iliadou A, Eriksson P, Hamsten A (1999) Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol 19:3063-3070
40. van Swieten JC, Hijdra A, Koudstaal PJ, van Gijn J (1990) Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psychiatry 53:1080-1083
41. Visser LE, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH (2005) Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 15:69-74
42. Wartiovaara U, Mikkola H, Szoke G, Haramura G, Karpati L, Balogh I, Lassila R, Muszbek L, Palotie A (2000) Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 84:595-600
43. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J (2006) Seven haemostatic gene polymorphisms in coronary disease: metaanalysis of 66, 155 cases and 91, 307 controls. Lancet 367:651-658